Role of N6-methyladenosine (m6A) modifications in Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and the accumulation of abnormal proteins, such as beta-amyloid plaques, in the brain. Epitranscriptomics, a branch of molecular biology, studies chemical modifications to RNA molecules and their impact on gene expression and cellular function. Among these modifications, N6-methyladenosine (m6A) plays crucial roles in various aspects of RNA metabolism, including RNA splicing, stability, translation, and localization. Dysregulation of m6A modification has been implicated in the development and progression of several diseases, including cancer and neurological disorders like AD.Our research focuses on studying enzymes involved in m6A modification, such as writers (methyltransferases), erasers (demethylases), and readers (m6A-binding proteins) in the context of human AD. Understanding the roles of these m6A-modifying enzymes in Alzheimer's disease may provide insights into the dysregulation of RNA metabolism and the development of potential therapeutic targets for AD. Further research is needed to elucidate the precise mechanisms by which m6A modifications and associated enzymes contribute to AD pathology.